VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES
THE ROLE OF VIDEO-ASSISTED THORACOSCOPIC SURGERY IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES
1 other identifier
observational
68
1 country
1
Brief Summary
Ovarian cancer is the seventh most common cancer and the fifth leading cause of death in women worldwide. About 70% of patients with epithelial ovarian cancer present with advanced disease which will require a combination of cytoreductive surgery and chemotherapy to give them their best chance of long term survival.The presence of macroscopic pleural disease-especially if undetected and unresected after primary debulking surgery-may alter treatment decision-making and markedly affect survival. Video-Assisted Thoracoscopic Surgery (VATS) allows surgeons, through a minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor. Few studies reported that VATS altered the therapeutic management in ovarian cancer patients leading to an upstaging or down-staging when compared to the CT staging. Therefore, this study will prospectively assess the role of VATS in the diagnosis and management of supradiaphragmatic disease as well as evaluate the impact of VATS findings on the decision of surgical management in patients with advanced ovarian cancer FIGO (The International Federation of Gynecology and Obstetrics) stage III/IV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2023
CompletedFirst Submitted
Initial submission to the registry
April 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2023
CompletedFirst Posted
Study publicly available on registry
May 3, 2023
CompletedMay 3, 2023
November 1, 2022
1.7 years
April 21, 2023
April 21, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prediction of intrathoracic disease using chest-CT results compared to the standard reference results using VATs
Comparison between the Chest-CT results in preoperative evaluation of supra-diaphragmatic disease will be compared to the intra-operative VATS evaluation results to evaluate the role of the VATS in those patients
3 weekS
Secondary Outcomes (1)
The rate of change in the treatment plan according to VATs results
1 week
Study Arms (2)
Group A: Patients who will get neoadjuvant chemotherapy based on VATS finding.
Patients will be considered to receive neoadjuvant chemotherapy if there is residual intrathoracic disease
Group B: Patients who will proceed into debulking surgery based on VATS finding.
Patients will be considered to be eligible for complete debulking, if VATS showed no intrathoracic tumor or if VATS achieves complete removal of tumor nodules through intraoperative frozen section histopathological examination.
Interventions
A minimally invasive approach, to not only drain the pleural effusion but also evaluate macroscopic pleural disease and, when possible, resect gross tumor.
Eligibility Criteria
Patients with advanced ovarian cancer at gyneoncology department will be enrolled
You may qualify if:
- FIGO stage III/IV ovarian cancer with or without pleural effusion
You may not qualify if:
- Previously treated ovarian disease.
- Patient unfit for single lung ventilation.
- Patients with previous lung surgery.
- Patients with possible intrapleural adhesions.
- Patients who had pulmonary resection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Alexandria University
Alexandria, 21131, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 21, 2023
First Posted
May 3, 2023
Study Start
June 1, 2021
Primary Completion
January 30, 2023
Study Completion
April 30, 2023
Last Updated
May 3, 2023
Record last verified: 2022-11